Skip to main content

Advertisement

SpringerLink
Log in

Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the efficacy of intravitreal anti-VEGF injections in choroidal neovascularization (CNV) related to pattern dystrophy-like deposit in pseudoxanthoma elasticum (PXE).

Methods

One-year prospective, interventional study. Nine eyes were recruited in the ophthalmology departments of San Raffaele University and University of Barcelona. Each patient underwent best corrected visual acuity (BCVA) measurement on ETDRS chart, slit-lamp biomicroscopy, fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT). The protocol included a first anti-VEGF injection, followed by monthly evaluations with re-treatments based on new funduscopic hemorrhages, fluid on OCT or leakage on FA and/or ICGA. Primary outcome measures were the mean BCVA changes. Secondary outcomes included central macular thickness (CMT) variations and the number of injections needed.

Results

At month 12, mean BCVA significantly improved from 20/45 to 20/35 Snellen equivalent, with 3 eyes gaining at least 3 ETDRS lines. Mean CMT decreased from 297 ± 22 to 262 ± 13 μm, after 5.5 ± 4.0 injections. No leakage was observed at the end of follow-up.

Conclusions

Intravitreal anti-VEGF injections represent an effective treatment for CNV related to pattern dystrophy-like deposit in PXE, with an improvement of BCVA and CMT. Mean injection number is in line with other studies performed in CNV secondary to angioid streaks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Uitto J, Bercovitch L, Terry SF, Terry PF (2011) Pseudoxanthoma elasticum: progress in diagnostics and research towards treatment: summary of the 2010 PXE International Research Meeting. Am J Med Genet A 155A:1517–1526

    Article  Google Scholar 

  2. Agarwal A, Patel P, Adkins T, Gass JD (2005) Spectrum of pattern dystrophy in pseudoxanthoma elasticum. Arch Ophthalmol 123:923–928

    Article  PubMed  Google Scholar 

  3. Battaglia Parodi MB, Iacono P, Bandello F (2015) Pseudoxanthoma elasticum associated with vitelliform macular lesion. Ophthalmic Surg Lasers Imaging Retina 46:287–288

    Article  Google Scholar 

  4. Battaglia Parodi M, Casalino G, Iacono P, Introini U, Adamyan T, Bandello F (2017) The expanding clinical spectrum of choroidal excavation in macular dystrophies. Retina. https://doi.org/10.1097/IAE.0000000000001805

  5. Clarkson JG, Altman RD (1982) Angioid streaks. Surv Ophthalmol 26:235–246

    Article  CAS  PubMed  Google Scholar 

  6. Lim JI, Bressler NM, Marsh MJ, Bressler SB (1993) Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 116:414–423

    Article  CAS  PubMed  Google Scholar 

  7. Pece A, Avanza P, Galli L, Brancato R (1997) Laser photocoagulation of choroidal neovascularization in angioid streaks. Retina 17:12–16

    Article  CAS  PubMed  Google Scholar 

  8. Wiegand TW, Rogers AH, McCabe F, Reichel E, Duker JS (2009) Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularization in patients with angioid streaks. Br J Ophthalmol 93:47–51

    Article  CAS  PubMed  Google Scholar 

  9. Da Pozzo S, Battaglia Parodi M, Toto L, Ravalico G (2001) Occult choroidal neovascularization in adult-onset foveomacular vitelliform dystrophy. Ophthalmologica 215:412–414

    Article  PubMed  Google Scholar 

  10. Zweifel SA, Imamura Y, Freund KB, Spaide RF (2011) Multimodal fundus imaging of pseudoxanthoma elasticum. Retina 31:482–491

    Article  PubMed  Google Scholar 

  11. Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P (2013) An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet 4:14

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tilleul J, Mimoun G, Querques G et al (2016) Intravitreal ranibizumab for choroidal neovascularization in angioid streaks: four-year follow-up. Retina 36:483–491

    Article  CAS  PubMed  Google Scholar 

  13. Alagöz C, Alagöz N, Özkaya A et al (2015) Intravitreal bevacizumab in the treatment of choroidal neovascular membrane due to angioid streaks. Retina 35:2001–2010

    Article  CAS  PubMed  Google Scholar 

  14. Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P (2013) Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina 33:1300–1314

    Article  CAS  PubMed  Google Scholar 

  15. Shah M, Amoaku WM (2012) Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks. Eye (Lond) 26:1194–1198

    Article  CAS  Google Scholar 

  16. Finger RP, Charbel Issa P, Hendig D, Scholl HP, Holz FG (2011) Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study. Am J Ophthalmol 152:695–703

    Article  CAS  PubMed  Google Scholar 

  17. El Matri L, Kort F, Bouraoui R, Karim B, Chebil A, Chaker N (2011) Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up. Acta Ophthalmol 89:641–646

    Article  CAS  PubMed  Google Scholar 

  18. Teixeira A, Mattos T, Velletri R et al (2010) Clinical course of choroidal neovascularization secondary to angioid streaks treated with intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 41:546–549

    Article  PubMed  Google Scholar 

  19. Mimoun G, Tilleul J, Leys A, Coscas G, Soubrane G, Souied EH (2010) Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Am J Ophthalmol 150:692–700

    Article  CAS  PubMed  Google Scholar 

  20. Iacono P, Battaglia Parodi M, La Spina C, Bandello F (2016) Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks: 3-year follow-up study. Am J Ophthalmol 165:174–178

    Article  CAS  PubMed  Google Scholar 

  21. Battaglia Parodi M, Iacono P, La Spina C et al (2014) Intravitreal bevacizumab for nonsubfoveal choroidal neovascularization associated with angioid streaks. Am J Ophthalmol 157:374–377

    Article  CAS  PubMed  Google Scholar 

  22. Vaclavik V, Tran HV, Gaillard MC, Schorderet DF, Munier FL (2012) Pattern dystrophy with high intrafamilial variability associated with Y141C mutation in the peripherin/RDS gene and successful treatment of subfoveal CNV related to multifocal pattern type with anti-VEGF (ranibizumab) intravitreal injections. Retina 32:1942–1949

    Article  CAS  PubMed  Google Scholar 

  23. Battaglia Parodi M, Iacono P, Cascavilla M, Zucchiatti I, Kontadakis DS, Bandello F (2010) Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Invest Ophthalmol Vis Sci 51:4358–4361

    Article  Google Scholar 

  24. Battaglia Parodi M, Di Crecchio L, Ravalico G (2000) Vascularized pigment epithelial detachment in adult-onset foveomacular vitelliform dystrophy. Eur J Ophthalmol 10:266–269

    Article  CAS  PubMed  Google Scholar 

  25. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Scientific Institute San Raffaele, University Vita-Salute, via Olgettina, 60, 20132, Milan, Italy

    Maurizio Battaglia Parodi, Francesco Romano, Alessandro Marchese, Alessandro Arrigo, Maria Vittoria Cicinelli & Francesco Bandello

  2. Institut Clínic d’Oftalmologia, Hospital Clínic de Barcelona, Barcelona, Spain

    Victor Llorenç & Alfredo Adán

Authors
  1. Maurizio Battaglia Parodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesco Romano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandro Marchese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Arrigo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Victor Llorenç
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Vittoria Cicinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francesco Bandello
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alfredo Adán
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandro Marchese.

Ethics declarations

Conflict of interest

Battaglia Parodi M has the following financial disclosures: Bausch & Lomb Inc. (C). Bandello F has the following financial disclosures: Alcon (C), Allergan Plc.(C), Famila-Thea (C), Bayer Schering Pharma AG (C), Bausch & Lomb (C), Hoffmann-La-Roche (C), Novartis (C), Sanofi-Aventis (C), and Carl Zeiss AG (C). FR, AM, AA, and MVC have no financial disclosures. Llorenç V has the following financial disclosures: Abbvie (G, C), Allergan(C), UCB(C). Adan A has the following financial disclosures: Abbvie (G, C), Allergan (G, C), UCB(C).

Ethical approval

The research was approved by the local Institutional Review Board and adhered to the tenets of the Declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Battaglia Parodi, M., Romano, F., Marchese, A. et al. Anti-VEGF treatment for choroidal neovascularization complicating pattern dystrophy-like deposit associated with pseudoxanthoma elasticum. Graefes Arch Clin Exp Ophthalmol 257, 273–278 (2019). https://doi.org/10.1007/s00417-018-4190-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-018-4190-7

Keywords

Search

Navigation